Online inquiry

IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ8939MR)

This product GTTS-WQ8939MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RL2 gene. The antibody can be applied in Lymphoproliferative disease research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Corynebacterium diphtheriae; Homo sapiens
RefSeq	NM_001351446.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	8808
UniProt ID	Q9HB29

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8939MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4703MR	IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	BMS-986168
GTTS-WQ6822MR	IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	DSTP-3086S
GTTS-WQ2760MR	IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	AMG162
GTTS-WQ10310MR	IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	LJM716
GTTS-WQ6820MR	IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	DSTP-3086S
GTTS-WQ13123MR	IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	PF-04360365
GTTS-WQ15170MR	IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	T1h
GTTS-WQ12695MR	IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	OMP-21M18

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST